Trial
NCT01428219
Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Michigan Rogel Cancer Center
Collaborators
Exelixis
Condition
Prostate Cancer Metastatic
Intervention
Cabozantinib
Why stopped
Closed due to slowing enrollment and negative results of a phase III trial using cabozantinib.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-12-12